Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 Inhibitor
Published: | Updated:
Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Robert Doebele, MD
Advertisement
Articles by Robert Doebele, MD
Advertisement
Latest Updated Articles
Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 InhibitorPublished: June 18th 2018 | Updated: December 19th 2020
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Accelerated Approval to Zongertinib in HER2+ NSCLC
2
Iza-Bren Yields Statistically Significant Efficacy in Advanced TNBC
3
Decoding Key Community Oncology Takeaways From ASCO GI 2026
4
Developer Terminates DHX9 Inhibitor Trial Amid Safety Concerns
5